La catena delle opzioni mostra i dati chiave delle opzioni azionarie di ACADIA Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ACADIA Pharmaceuticals..

ACADIA Pharmaceuticals (NASDAQ:ACAD) Azioni, Catena delle Opzioni

ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals Inc

ACADIA PHARMACEUTICALS ORD

ACADIA HEALTHCARE COMPANY ORD

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports and Outdoors Inc

ACADIA ENERGY CORP by Acadia Energy Corporation

Acadia Energy Corp

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

Acadia Realty Trust

ACADIAN TIMBER CORP ORD by Acadian Timber Corp

Acadian Timber Corp

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

News

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Acadia Pharmaceuticals Announces Health Canada Approval Of DAYBUE For Treatment Of Rett Syndrome

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $25.0, a high estimate of $28.00, and a low estimate of $20.00. Experiencing a 15.05% decline, the current average is now lower than the previous average price target of $29.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1728565226_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive ACADIA Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ACADIA Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ACADIA Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ACADIA Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind ACADIA Pharmaceuticals</h2>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 46.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.8%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.81%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ACADIA Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 3.77%. This signifies efficient management of assets and strong financial health.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know

Raymond James analyst Danielle Brill reinstates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Market Perform.

Initiation

Raymond James Reinstates Market Perform on ACADIA Pharmaceuticals

A large exercise of company stock options by Owen Catherine Adams, Chief Executive Officer at ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) was disclosed in a new SEC filing on September 25, as part of an insider exercise.
What Happened: The latest Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001070494/000141588924023975//Archives/edgar/data/1070494/000141588924023975/0001415889-24-023975-index.htm">U.S. Securities and Exchange Commission</a> uncovered Adams, Chief Executive Officer at ACADIA Pharmaceuticals, exercising stock options for 0 shares of ACAD. The total transaction was valued at $0.
The Thursday morning market activity shows ACADIA Pharmaceuticals shares up by 1.24%, trading at $15.51. This implies a total value of $0 for Adams's 0 shares.
<h3>Unveiling the Story Behind ACADIA Pharmaceuticals</h3>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>A Deep Dive into ACADIA Pharmaceuticals's Financials</h3>
Revenue Growth: Over the 3 months period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 46.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 92.47%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): ACADIA Pharmaceuticals's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.2.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 80.63 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.85, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): ACADIA Pharmaceuticals's EV/EBITDA ratio at 61.21 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001070494">Check Out The Full List Of ACADIA Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Notable Insider Move: Owen Catherine Adams Takes Part In Options Exercise At ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares are trading lower by 4.11% to $15.62 during Tuesday&#8217;s session after the company <a href="https://www.benzinga.com/pressreleases/24/09/b40991009/catherine-owen-adams-succeeds-steve-davis-as-ceo-of-acadia-pharmaceuticals">appointed</a> Catherine Owen Adams as CEO.
What Happened: Acadia Pharmaceuticals announced that Catherine Owen Adams has succeeded Steve Davis as CEO and joined the board of directors. Acadia says Catherine brings extensive leadership experience from her roles at Bristol Myers Squibb and Johnson &amp; Johnson, where she oversaw significant growth and product launches. 
The board meanwhile expressed confidence in Adams&#8217; ability to drive Acadia&#8217;s next phase of growth, emphasizing her strategic vision and commitment to patient outcomes. Steve Davis was also thanked for his leadership, particularly for his role in the approval and commercialization of NUPLAZID and DAYBUE. 
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40993290/trump-vs-harris-2024-election-betting-odds-show-vice-president-maintains-lead-as-race-near">Trump Vs. Harris: 2024 Election Betting Odds Show Vice President Maintains Lead As Race Nears One-Month Mark</a>
<h2 class="wp-block-heading">Is ACAD A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/ACAD">ACADIA Pharmaceuticals</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. ACADIA Pharmaceuticals does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 11.7%, you'll need to buy a share of New York Mortgage Trust by the Sep. 30, 2024. Once done, you can expect to receive a nominal payout of $0.2 on Oct. 28, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/ACAD">ACADIA Pharmaceuticals</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ACAD has a 52-week high of $32.59 and a 52-week low of $14.55.

What's Going On With ACADIA Pharmaceuticals Stock?

WIIM

ACADIA Pharmaceuticals shares are trading lower after the company appointed Catherine Owen Adams as CEO.

Management

Acadia Pharmaceuticals Appoints Catherine Owen Adams As CEO

Axcelead DDP has already been engaged in multiple drug discovery projects in the neuroscience area to identify candidate compounds since October 2022. Acadia and Axcelead DDP have entered into the Master Service Agreement so that Axcelead DDP can more efficiently and comprehensively support certain new drug discovery projects of Acadia. Axcelead DDP will provide drug discovery support to Acadia by leveraging its integrated drug discovery platform, deep knowledge and extensive experience in drug discovery research to potentially generate high-quality candidate compounds.
A new drug discovery project under the executed MSA has been launched at the same time. Axcelead DDP will receive an upfront fee, research funding and milestone fees as in the previous projects. Details of the financial terms regarding the Master Service Agreement and the new project are not disclosed.

Biotech

Contracts

General

Axcelead Drug Discovery Partners Enters Into Master Service Agreement For Drug Discovery Projects With Acadia Pharmaceuticals To Support Their Goal Of Discovering And Developing Innovative And Novel Medicines To Help Address Unmet Medical Needs; No Financial Terms Disclosed

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer called e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) &#8220;without a doubt, one of the most shorted stocks in the market.&#8221;
&#8220;And every time anything bad happens in the cosmetic group, people<a href="https://www.benzinga.com/quote/ELF/news"> </a>come down on it, but then <a href="https://www.benzinga.com/quote/ELF/news">you have to buy,&#8221; he said.</a>
Cramer said he doesn't like B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>). &#8220;It's just really a bunch of warmed over brands put together under one roof. That game doesn't work anymore,&#8221; he added.
The &#8220;Mad Money&#8221; host said Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) has &#8220;just had a major move up. Every time it's had a major move up, it then moves down.&#8221; He recommended waiting until it comes down a little bit. &#8220;It's too high for me,&#8221; he added.
Cramer recommended to wait for a pullback, when asked about UWM Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NASDAQ">UWMC</a>).
Cramer recommended not touching Symbotic Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NYSE">SYM</a>). &#8220;The company is not the one you want to be in. It is too high, even after this comedown,&#8221; he noted.
ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) is a trading stock and not an investment stock, Cramer said. &#8220;It's just too high risk for me,&#8221; he added.
&#8220;I am believing that SoFi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) may be the right one,&#8221; Cramer said. &#8220;I see the risk reward to be very positive.&#8221;
Cramer said he believes in Michael Dell, CEO of Dell, and recommended buying Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>).
Cramer recommended selling Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
Price Action:
<ul>
<li>E.l.f Beauty shares fell 8.7% to settle at $156.09 on Monday.</li>
<li>Acadia Pharmaceuticals shares gained 0.9% to close at $16.09.</li>
<li>B&amp;G Foods shares gained 2.6% to close at $8.63.</li>
<li>Lucid shares gained 1.4% to settle at $4.26 on Monday.</li>
<li>SoFi shares gained 2% to settle at $7.67.</li>
<li>Dell shares 0.3% to close at $111.67.</li>
<li>Johnson &amp; Johnson shares rose 0.3% to settle at $164.61 on Monday.</li>
<li>UWM shares fell 2% to close at $9.33.</li>
<li>Symbotic shares fell 2.5% to settle at $22.77.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40551343/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Long Ideas

Markets

Media

DELL

LCID

SOFI

UWMC

Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods

On August 20, a recent SEC filing unveiled that STEPHEN DAVIS, CEO at ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) made an insider sell.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001070494/000141588924021724//Archives/edgar/data/1070494/000141588924021724/0001415889-24-021724-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that DAVIS executed a sale of 31,747 shares of ACADIA Pharmaceuticals with a total value of $485,094.
The latest update on Wednesday morning shows ACADIA Pharmaceuticals shares up by 0.39%, trading at $15.63.
<h3>Unveiling the Story Behind ACADIA Pharmaceuticals</h3>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals: A Financial Overview</h3>
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 46.44%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 92.47%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): ACADIA Pharmaceuticals's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.2.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.11, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 81.95 is lower than the industry average, implying a discounted valuation for ACADIA Pharmaceuticals's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.89, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 62.42, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001070494">Check Out The Full List Of ACADIA Pharmaceuticals's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CEO At ACADIA Pharmaceuticals Sells $485K Of Stock

Brendan Teehan, EVP at ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), disclosed an insider sell on August 20, according to a recent SEC filing.
What Happened: Teehan's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001070494/000141588924021726//Archives/edgar/data/1070494/000141588924021726/0001415889-24-021726-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled the sale of 9,534 shares of ACADIA Pharmaceuticals. The total transaction value is $145,679.
The latest update on Wednesday morning shows ACADIA Pharmaceuticals shares up by 0.39%, trading at $15.63.
<h3>About ACADIA Pharmaceuticals</h3>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals's Economic Impact: An Analysis</h3>
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 46.44%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 92.47%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): ACADIA Pharmaceuticals's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.2.
</li>
</ul>
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 81.95 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.89, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 62.42, ACADIA Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001070494">Check Out The Full List Of ACADIA Pharmaceuticals's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVP Of ACADIA Pharmaceuticals Sold $145K In Stock

Revealing a significant insider sell on August 20, Mark Schneyer, EVP at ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), as per the latest SEC filing.
What Happened: After conducting a thorough analysis, Schneyer sold 9,733 shares of ACADIA Pharmaceuticals. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001070494/000141588924021731//Archives/edgar/data/1070494/000141588924021731/0001415889-24-021731-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total transaction value is $148,720.
During Wednesday's morning session, ACADIA Pharmaceuticals shares up by 0.39%, currently priced at $15.63.
<h3>About ACADIA Pharmaceuticals</h3>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals: A Financial Overview</h3>
Revenue Growth: ACADIA Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 46.44%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: With a high gross margin of 92.47%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): ACADIA Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.2.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.11, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 81.95 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 2.89 is lower than the industry average, implying a discounted valuation for ACADIA Pharmaceuticals's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 62.42, ACADIA Pharmaceuticals presents an attractive value opportunity.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001070494">Check Out The Full List Of ACADIA Pharmaceuticals's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Mark Schneyer Implements A Sell Strategy: Offloads $148K In ACADIA Pharmaceuticals Stock

Axsome Therapeutics&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder, making it the first approved drug in the company&#39;s portfolio.
The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand. The momentum is likely to continue for the remainder of 2024.
Axsome is also conducting several label expansion studies on Auvelity targeting other central nervous system&nbsp;disorders like Alzheimer&#39;s disease (AD) associated agitation and smoking cessation.
Currently, two separate phase III studies are evaluating Auvelity for treating agitation associated with AD. Top-line data from both studies are expected later in the second half of 2024.
AXSM is planning to initiate a phase II/III pivotal study on AXS-05 for smoking cessation later in 2024.
The successful development and subsequent commercialization of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.
Axsome acquired U.S. rights to Sunosi, a commercialized drug targeting narcolepsy, from Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome&#39;s portfolio to two marketed drugs. In the first half of 2024, Sunosi&#39;s net product sales were $42.2 million, reflecting an increase of almost 35.2% year over year. Sunosi has become an important revenue driver for Axsome.
In February 2023, AXSM entered into a licensing agreement with Pharmanovia to market Sunosi in Europe and certain Middle East/North African countries. Axsome receives royalties on Sunosi sales in out-licensed territories.
Axsome has an impressive portfolio of pipeline candidates, including AXS-07, AXS-12 and AXS-14. All of these are being developed for various CNS indications.
AXS-07 is being developed for the acute treatment of migraine. After several delays, the company resubmitted its NDA for AXS-07 to the FDA for the acute treatment of migraine in the second quarter of 2024. A decision from the regulatory body is expected within six months.
Though Axsome is riding on the success of Auvelity and Sunosi, competition looms large on the company in the target market as many companies are developing treatments to address various CNS disorders. One such company is Acadia Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acad#NASDAQ">ACAD</a>), which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications.
ACAD&#39;s Nuplazid is already approved for hallucinations and delusions associated with Parkinson&#39;s disease psychosis.
Acadia is also studying pimavanserin for the treatment of other CNS disorders.
<a href="https://www.zacks.com/stock/news/2322688/axsome-axsm-banks-on-auvelity-sunosi-to-fuel-growth?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2322688">To read this article on Zacks.com click here.</a>

Mid Cap

AXSM

JAZZ

Axsome Banks on Auvelity & Sunosi to Fuel Growth

Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $30 to $23.

Price Target

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $23

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $25 to $23.

UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $23

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $27 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $30 to $28.

Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $28

Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Overweight and lowers the price target from $37 to $28.

Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $28

Tracking Baker Brothers Portfolio - Q2 2024 Update

Catherine Owen appointed as CEO of Acadia Pharmaceuticals

The latest announcement is out from ACADIA Pharmaceuticals ( ($ACAD) ). Acadia Pharmaceuticals Inc. announced the departure of Stephen R. Davis as ...

ACADIA Pharmaceuticals Welcomes New CEO, Unveils Compensation Plan

In a report released yesterday, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Assessing ACADIA Pharmaceuticals Amidst Leadership Transition and Pipeline Prospects: A Hold Rating Recommendation

With the growing demand for innovative healthcare services, increasing spending, and rising tech adoption, the healthcare market is booming. Amid this backdrop, investors could check out quality healthcare stocks ACADIA Pharmaceuticals (ACAD), Harvard Bioscience (HBIO), and LAVA Therapeutics (LVTX), which have significant upside potential. Continue reading... Given the growing healthcare expenditure globally due to the rising aging population and growing prevalence of chronic and rare diseases, coupled with innovative solutions, the healthcare industry is positioned for continued growth and expansion. Also, advanced technologies like AI and IoT are transforming the market.
Given the industry's rosy prospects, it could be wise to invest in fundamentally strong healthcare stocks ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>), Harvard Bioscience, Inc. (<a href="https://stocknews.com/stock/HBIO/">HBIO</a>), and LAVA Therapeutics N.V. (<a href="https://stocknews.com/stock/LVTX/">LVTX</a>) poised for significant upside.
<a href="https://www.healthsystemtracker.org/brief/policy-issues-and-trends-2024/#Total%20out-of-pocket%20retail%20prescription%20drug%20spending,%20projections%20before%20&amp;amp;%20after%20passage%20of%20the%20Inflation%20Reduction%20Act">Healthcare spending in the U.S. is expected to grow by 5%</a> between 2023 and 2024, reaching $4.90 trillion.
The healthcare market is transforming with constantly evolving government regulations and policies, <a href="https://appinventiv.com/blog/healthcare-app-trends/">innovative solutions, and rapid technological advancements</a> paving new directions for the industry. Emerging healthcare technologies like artificial intelligence, IoT, and blockchain offer advantages for both patients and practitioners by lowering costs and increasing efficiency.
As per Statista, revenue in the pharmaceuticals market is projected to hit $1.15 trillion in 2024. In global comparison, the highest revenue will be generated in the U.S. owing to advanced healthcare infrastructure and strong R&amp;D capabilities of nearly $630.30 billion. The <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">global pharmaceuticals market revenue</a> is anticipated to increase at a CAGR of 4.7%, reaching $1.45 trillion by 2029.
Further, the global AI in healthcare market is estimated to value $148.40 billion by 2029, expanding at a <a href="https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html">CAGR of 48.1%</a> driven by the need to reduce costs, increasing partnerships and collaborations among healthcare companies, and the growing demand for improvised healthcare services.
Moreover, investors' interest in the healthcare industry is evident from SPDR Select Sector Fund - Health Care (<a href="https://stocknews.com/stock/XLV/">XLV</a>) 20.7% return over the past year.
Given the industry's bright prospects, healthcare stocks like ACAD, HBIO, and LVTX look poised to soar.
Let's discuss the fundamentals of these stocks in detail:
ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>)
ACAD is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
On July 18, ACAD reported the published results from the journal Med regarding the two open-label extension studies, LILAC-1&#x2122; and LILAC-2&#x2122;, which showed that patients treated with DAYBUE&#x2122; who completed these studies experienced improvement in Rett symptoms as measured by the Rett Syndrome Behaviour Questionnaire.
For the second quarter that ended June 30, 2024, ACAD's <a href="https://www.investopedia.com/terms/r/revenue.asp">total revenues</a> increased 46.4% year-over-year to $241.96 million. Its income from operations rose 902.2% from the year-ago value to $30.44 million. The company's net income and EPS came in at $33.39 million and $0.20, up 2897.2% and 1900% from the prior year's quarter, respectively.
In addition, the company's cash, cash equivalents, and investment securities were $500.94 million as of June 30, 2024, compared to $438.86 million as of December 31, 2023.
Street expects ACAD's revenue for the fiscal year ending December 2025 to increase 11.4% year-over-year to $1.06 billion. Its EPS for fiscal 2025 is expected to rise 56.1% year-over-year to $0.85. Also, the company topped the consensus revenue and EPS estimates in three of the trailing four quarters.
Shares of ACAD have declined marginally over the past month to close the last trading session at $15.84. The average analyst price target of $26.93 indicates a <a href="https://www.tipranks.com/stocks/acad/forecast">70% upside potential</a>.
ACAD's robust growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, ACAD is ranked #15 out of 157 stocks.
<a href="https://stocknews.com/stock/ACAD/">Click here</a> to access additional ratings of ACAD for Sentiment, Stability, and Momentum.
Harvard Bioscience, Inc. (<a href="https://stocknews.com/stock/HBIO/">HBIO</a>)
HBIO develops, manufactures, and sells technologies, products, and services for life science applications internationally. It offers cellular and molecular technology products, electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular-level testing and research.
During the second quarter, HBIO launched its latest product innovations. These included the DSI&#x2122; Ponemah&#x2122; data management platform, which provides an integrated preclinical solutions. It also launched SoHo&#x2122; implantable real-time telemetry for small animal models, VivaMARS&#x2122;, which is an activity monitoring system.
The new solutions for CROs, pharma, and biotech streamline testing and enable fundamental advancements in preclinical and organoid-focused therapy development.
HBIO reported revenues of $23.10 million during the second quarter that ended June 30, 2024, and its gross profit was $13.22 million. The company's adjusted operating stood at $818 thousand for the quarter. The company's cash and cash equivalents and total assets came in at $4.05 million and $128.91 million as of June 30, 2024.
Analysts expect HBIO's revenue for the fiscal year (ending December 2025) to increase 9.3% year-over-year to $106.85 million, and its EPS for the same year is expected to grow 100% year-over-year to $0.15.
HBIO's shares have plunged 10.9% over the past month to close the last trading session at $2.70. Wall Street analysts expect the stock to hit $6.25 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/hbio/forecast">upside of 131.5%</a>.
HBIO's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Value. Within the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical – Diagnostics/Research</a> industry, HBIO is ranked #20 among the 39 stocks.
In addition to the POWR Ratings we've stated above, we also have HBIO ratings for Quality, Growth, Momentum, Stability, and Sentiment. Get all HBIO ratings <a href="https://stocknews.com/stock/HBIO/">here</a>.
LAVA Therapeutics N.V. (<a href="https://stocknews.com/stock/LVTX/">LVTX</a>)
Headquartered in Utrecht, Netherlands, LVTX is a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
During the second quarter, LVTX reported continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combination. It also mentioned the safety profile for LAVA-1207.
During the six months, which ended June 30, 2024, LVTX's revenue from contracts with customers increased 9.9% year-over-year to $6.99 million. Its gross profit grew 129.6% from the year-ago value to $6.99 million. The company's total non-operating income came in at $2.62 million, reflecting growth of 327.8% year-over-year.
Furthermore, the company's cash and cash equivalents and total assets stood at $35.09 million and $92.28 million as of June 30, 2024.
LVTX's stock has soared 11.2% over the past year to close the last trading session at $1.69. Wall Street analysts expect the stock to hit $6 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/lvtx/forecast">upside of 255%</a>.
LVTX's POWR Ratings reflect its robust outlook. LVTX has an A grade for Sentiment. It also has a B grade for Value. It is ranked #73 among the 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/LVTX/">Click here</a> to access additional LVTX ratings for Growth, Stability, Quality, and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ACAD shares were trading at $15.35 per share on Wednesday afternoon, down $0.49 (-3.09%). Year-to-date, ACAD has declined -50.97%, versus a 21.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/acad-hbio-lvtx-3-healthcare-stocks-analysts-expect-to-rally-over-50/>3 Healthcare Stocks Analysts Expect to Rally Over 50%</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks Analysts Expect to Rally Over 50%

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA Pharmaceutic...

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a pr...

Morgan Stanley Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD)

Acadia Pharmaceuticals (ACAD) "announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Rev...

Comments

ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (ACAD) Opzioni

ACADIA Pharmaceuticals (NASDAQ:ACAD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO